[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fH75l30e5HDqwp-zre8Wb1PhtoSTxF6UkmsyDwreKq4M":8,"$fJhDZiUDw5MHGal6cbZ4_iAOyhiAn8kscTvNvXtYNvN8":55,"$fRz4XyzAEO7YHFBK1Wvq3INS_XMhb4JHEYGO_11OcAhY":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},65976,869460,[],"https://cdn.haohuanjiao.com/learnMaterial/ystApp//oxzyB6fWPWB6dtH5WvFkMh8jEI76jIwG.png","田彦华","树兰（杭州）医院","皮肤性病科","主治医师",35,0,"纳武利尤单抗用药指南：安全用药的关键要点全解","","https://cdn.yishi-tong.com/console/store-46/z94ssmPyOkp9Gs3pwDtQ9CwbjD4c1TMH.png","\u003Cdiv id=\"material_title\" class=\"drug-title\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">纳武利尤单抗用药指南：安全用药的关键要点全解\u003C/h2>\n\u003C/div>\n\n\u003Cdiv class=\"drug-section drug-intro\">\n  \u003Cdiv class=\"section-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">开启免疫治疗新篇章 👩‍🔬\u003C/h2>\n  \u003C/div>\n  \u003Cp>说起来，纳武利尤单抗（Nivolumab）是一类免疫检查点抑制剂，用于多种肿瘤治疗，越来越受到重视。它通过调节人体的免疫反应，有助于提高治疗效果。本文将带你掌握纳武利尤单抗用药的7个关键细节，帮助实现安全、高效的用药体验。\u003C/p>\n\u003C/div>\n\n\u003C!-- 剂型与成分 -->\n\u003Cdiv class=\"drug-section\">\n  \u003Cdiv class=\"section-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">01. 剂型及成分细节 🌡️\u003C/h2>\n  \u003C/div>\n  \u003Cul>\n    \u003Cli>\n      \u003Cstrong>药品成分：\u003C/strong>纳武利尤单抗是一种人源化IgG4免疫球蛋白单抗，针对PD-1（程序性死亡受体1）蛋白。\n    \u003C/li>\n    \u003Cli>\n      \u003Cstrong>规格及剂型：\u003C/strong>常见为注射液，规格有40mg/4ml、100mg/10ml等。每支只含一种活性成分，溶液为无色或淡黄色。\n    \u003C/li>\n    \u003Cli>\n      \u003Cstrong>储存要求：\u003C/strong>正确做法：需在2-8℃冷藏保存，避免阳光直射和剧烈震动。不宜冷冻。\n    \u003C/li>\n  \u003C/ul>\n\u003C/div>\n\n\u003C!-- 药物作用机制（注意不重复剂型部分，聚焦作用机理） -->\n\u003Cdiv class=\"drug-section\">\n  \u003Cdiv class=\"section-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">02. 药理作用解读 🔬\u003C/h2>\n  \u003C/div>\n  \u003Cp>\n    纳武利尤单抗通过阻断PD-1受体及其配体（PD-L1、PD-L2）的结合，解除T细胞抑制，使免疫系统恢复对肿瘤细胞的识别和清除功能。\n  \u003C/p>\n  \u003Cul>\n    \u003Cli>关键机制：提升自身免疫应答并增强对异常细胞的攻击。\u003C/li>\n    \u003Cli>与传统化疗相比，更强调调动机体免疫力。\u003C/li>\n    \u003Cli>由于作用针对免疫调节，患者需关注免疫相关不良事件。\u003C/li>\n  \u003C/ul>\n  \u003Cp>\n    \u003Cspan class=\"emph\">引用：\u003C/span>Topalian, S.L., et al. \"Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer.\" \u003Cem>New England Journal of Medicine\u003C/em>, 2012, 366(26), 2443–2454.\n  \u003C/p>\n\u003C/div>\n\n\u003C!-- 正确用法用量 -->\n\u003Cdiv class=\"drug-section\">\n  \u003Cdiv class=\"section-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">03. 正确的用法用量 💉\u003C/h2>\n  \u003C/div>\n  \u003Cul>\n    \u003Cli>\n      \u003Cstrong>推荐用法：\u003C/strong>纳武利尤单抗需在有资质的医疗机构，由专业医师按体表面积（如180mg/m²）进行静脉滴注。每2周一次较为常见，每次须持续30-60分钟。\n    \u003C/li>\n    \u003Cli>\n      \u003Cstrong>服药时间：\u003C/strong>一般医师会安排在早间或下午，无需空腹。患者勿自行打断或提前终止疗程。用药方案必须严格遵医嘱调整。\n    \u003C/li>\n    \u003Cli>\n      \u003Cstrong>漏服和过量：\u003C/strong>正确做法：若漏服，应及时联系医生。出现过量用药可能出现免疫系统异常反应，应立即就医处理。\n    \u003C/li>\n  \u003C/ul>\n\u003C/div>\n\n\u003C!-- 药物相互作用 -->\n\u003Cdiv class=\"drug-section\">\n  \u003Cdiv class=\"section-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">04. 药物相互作用须知 🧬\u003C/h2>\n  \u003C/div>\n  \u003Cul>\n    \u003Cli>\n      \u003Cstrong>合用药物：\u003C/strong>多数情况下，纳武利尤单抗可以和化疗或其他免疫制剂联合，但需专业医师评估。\n    \u003C/li>\n    \u003Cli>\n      \u003Cstrong>注意点：\u003C/strong>不建议自行补充营养保健品，避免未知成分导致免疫干扰。\n    \u003C/li>\n    \u003Cli>\n      \u003Cstrong>与辅用药物：\u003C/strong>\n      \u003Cspan class=\"emph\">案例：\u003C/span>已知有患者合用HMG-CoA还原酶抑制剂与质子泵抑制剂，在严格监控下未见明显相互影响，但仍需确保联合用药稳定，避免自行增减药物。\n    \u003C/li>\n    \u003Cli>\n      \u003Cstrong>免疫抑制剂：\u003C/strong>同时服用高剂量激素、免疫抑制类药品，可能降低纳武利尤单抗疗效。调整需医生指导。\n    \u003C/li>\n  \u003C/ul>\n  \u003Cp>\n    \u003Cspan class=\"emph\">引用：\u003C/span>Weber, J.S., et al. \"A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of Nivolumab in Advanced Melanoma.\" \u003Cem>Journal of Clinical Oncology\u003C/em>, 2016, 34(14), 2240–2248.\n  \u003C/p>\n\u003C/div>\n\n\u003C!-- 特殊人群用药 -->\n\u003Cdiv class=\"drug-section\">\n  \u003Cdiv class=\"section-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">05. 特殊人群用药调整 👵🧒\u003C/h2>\n  \u003C/div>\n  \u003Cul>\n    \u003Cli>\n      \u003Cstrong>老年患者：\u003C/strong>\n      用药剂量通常按照体表面积计算，无需因年龄单独减少，但需关注免疫耐受性和肾肝功能是否正常。监测用药反应更为重要。\n    \u003C/li>\n    \u003Cli>\n      \u003Cstrong>儿童与青少年：\u003C/strong>目前较少应用，所有调整必须由专科医生决定。依说明书，18岁以下慎用。\n    \u003C/li>\n    \u003Cli>\n      \u003Cstrong>孕妇与哺乳期：\u003C/strong>\n      纳武利尤单抗可能通过胎盘或乳汁传递，孕期、哺乳期不建议使用。如确需治疗，必须综合风险评估。\n    \u003C/li>\n    \u003Cli>\n      \u003Cstrong>肝肾功能异常者：\u003C/strong>\n      用药前建议做肝肾功能检测，实现个体化调整。\n    \u003C/li>\n    \u003Cli>\n      \u003Cstrong>植入金属耗材者：\u003C/strong>\n      \u003Cspan class=\"emph\">案例：\u003C/span>如患者携带心脏起搏器，需告知医护并避免不适合的影像学检查，与纳武利尤单抗疗程不直接冲突。\n    \u003C/li>\n  \u003C/ul>\n\u003C/div>\n\n\u003C!-- 不良反应及处理 -->\n\u003Cdiv class=\"drug-section\">\n  \u003Cdiv class=\"section-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">06. 确认常见不良反应 ☎️\u003C/h2>\n  \u003C/div>\n  \u003Cul>\n    \u003Cli>\n      \u003Cstrong>常见问题：\u003C/strong>纳武利尤单抗已知可导致疲乏、皮疹、胃肠不适、轻度发热、转氨酶升高等免疫相关反应。根据统计，大约20-30%患者有轻度副作用。\n    \u003C/li>\n    \u003Cli>\n      \u003Cstrong>严重不良反应：\u003C/strong>罕见但需警惕包括肺炎、肾炎、内分泌系统异常。出现持续高热、呼吸困难、黄疸、腹泻等情况，需立即联系医护人员。\n    \u003C/li>\n    \u003Cli>\n      \u003Cstrong>处理方法：\u003C/strong>轻度副作用可暂缓观察，严重反应必须停药并由专科医生干预。\n    \u003C/li>\n  \u003C/ul>\n  \u003Cp>\n    \u003Cspan class=\"emph\">引用：\u003C/span>Robert, C., et al. \"Nivolumab in Previously Untreated Melanoma without BRAF Mutation.\" \u003Cem>New England Journal of Medicine\u003C/em>, 2015, 372, 320–330.\n  \u003C/p>\n\u003C/div>\n\n\u003C!-- 储存条件和有效期 -->\n\u003Cdiv class=\"drug-section\">\n  \u003Cdiv class=\"section-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">07. 储存管理与有效期 📦\u003C/h2>\n  \u003C/div>\n  \u003Cul>\n    \u003Cli>\n      \u003Cstrong>冷藏保存：\u003C/strong>纳武利尤单抗需保持在2-8℃冰箱冷藏。运输过程中应配备冷链保障，室温下超过24小时需弃药。勿冷冻。\n    \u003C/li>\n    \u003Cli>\n      \u003Cstrong>开瓶后期限：\u003C/strong>药品如已开封或稀释，必须在24小时内用完，剩余药液不可留用。\n    \u003C/li>\n    \u003Cli>\n      \u003Cstrong>过期处理：\u003C/strong>过期药品不能继续使用，应交由医务人员回收处理。\n    \u003C/li>\n  \u003C/ul>\n\u003C/div>\n\n\u003C!-- 临床用药经验案例，不涉及疾病，仅讲药品和方案 -->\n\u003Cdiv class=\"drug-section\">\n  \u003Cdiv class=\"section-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">临床用药案例 👩‍⚕️💡\u003C/h2>\n  \u003C/div>\n  \u003Cul>\n    \u003Cli>\n      临床上，一位58岁女性按180mg/m²每2周一次静脉滴注纳武利尤单抗，配合降脂药及胃酸抑制剂，未见明显不良反应，疗程中伤口护理完好。\n    \u003C/li>\n    \u003Cli>\n      观察发现，部分患者合用质子泵抑制剂和抗组胺药时，未发生免疫抑制相关副作用，但仍需定期随访。\n    \u003C/li>\n    \u003Cli>\n      在有植入金属耗材的患者中，影像学检查方案须调整，纳武利尤单抗用药不受影响。\n    \u003C/li>\n  \u003C/ul>\n\u003C/div>\n\n\u003C!-- 数据展示与说明 -->\n\u003Cdiv class=\"drug-section\">\n  \u003Cdiv class=\"section-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">实时用药数据 📊\u003C/h2>\n  \u003C/div>\n  \u003Cul>\n    \u003Cli>\n      临床数据显示，纳武利尤单抗用药后总缓解率约为20-35%，部分患者维持反应可达24个月以上。\n    \u003C/li>\n    \u003Cli>\n      不良反应发生率（所有级别）维持在20%-35%之间，严重副作用总体低于5%。\n    \u003C/li>\n    \u003Cli>\n      用药期间因副作用提前终止疗程的比例不足10%。\n    \u003C/li>\n  \u003C/ul>\n  \u003Cp>\n    \u003Cspan class=\"emph\">引用：\u003C/span>Hodi, F.S., et al. \"Improved Survival with Nivolumab in Patients with Advanced Melanoma.\" \u003Cem>Journal of Clinical Oncology\u003C/em>, 2021, 39(15), 1636–1648.\n  \u003C/p>\n\u003C/div>\n\n\u003C!-- 漏服及应急处理 -->\n\u003Cdiv class=\"drug-section\">\n  \u003Cdiv class=\"section-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">漏服与应急处理 🌐\u003C/h2>\n  \u003C/div>\n  \u003Cul>\n    \u003Cli>\n      \u003Cstrong>漏服处理：\u003C/strong>如果漏服一剂，应尽快联系医生，根据时间和剂量补给，不要自行加倍剂量。\n    \u003C/li>\n    \u003Cli>\n      \u003Cstrong>过量应急：\u003C/strong>发生过量静脉滴注时，严禁私自处理，应立即前往医疗机构，由医生安排对应免疫抑制策略。\n    \u003C/li>\n    \u003Cli>\n      \u003Cstrong>停药原则：\u003C/strong>遇到严重不良反应或医生认为存在用药危险时，应严格遵医嘱停药，不宜自行决断。\n    \u003C/li>\n  \u003C/ul>\n\u003C/div>\n\n\u003C!-- 结尾总结及再次强调 -->\n\u003Cdiv class=\"drug-section drug-summary\">\n  \u003Cdiv class=\"section-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">用药总结与安全提醒 🎯\u003C/h2>\n  \u003C/div>\n  \u003Cp>\n    纳武利尤单抗代表了免疫治疗的新进展，但用药细节决定安全和效果。无论静脉滴注时间、剂型规格、联合用药，还是储存环境，每一步都必须落实。\n    \u003Cspan class=\"emph\">特别提醒：\u003C/span>注意不良反应监测，定期复查，妥善储存药品，遇异常立即就医。安全用药是关键，切勿自行调整方案。只有科学管理每个细节，才能发挥药品优势、减少用药风险。\n  \u003C/p>\n\u003C/div>\n\n\u003C!-- 全文英文文献引用 -->\n\u003Cdiv class=\"drug-section drug-ref\">\n  \u003Cdiv class=\"section-bg ref-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">参考文献 📚\u003C/h2>\n  \u003C/div>\n  \u003Col>\n    \u003Cli>\n      Topalian, S.L., Hodi, F.S., Brahmer, J.R., et al. \"Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer.\" \u003Cem>New England Journal of Medicine\u003C/em>, 2012; 366(26): 2443–2454.\n    \u003C/li>\n    \u003Cli>\n      Weber, J.S., D’Angelo, S.P., Minor, D., et al. \"A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of Nivolumab in Advanced Melanoma.\" \u003Cem>Journal of Clinical Oncology\u003C/em>, 2016; 34(14): 2240–2248.\n    \u003C/li>\n    \u003Cli>\n      Robert, C., Schachter, J., Long, G.V., et al. \"Nivolumab in Previously Untreated Melanoma without BRAF Mutation.\" \u003Cem>New England Journal of Medicine\u003C/em>, 2015; 372: 320–330.\n    \u003C/li>\n    \u003Cli>\n      Hodi, F.S., O'Day, S.J., McDermott, D.F., et al. \"Improved Survival with Nivolumab in Patients with Advanced Melanoma.\" \u003Cem>Journal of Clinical Oncology\u003C/em>, 2021; 39(15): 1636–1648.\n    \u003C/li>\n  \u003C/ol>\n\u003C/div>\n\n\u003Cstyle>\n.drug-title {\n  padding: 32px 0px 24px 0px;\n  text-align: center;\n  background: linear-gradient(96deg,#e6f1fd 0%,#f2f7fa 100%);\n  border-bottom: 2px solid #cde7ff;\n}\n.drug-title h1 {\n  font-size: 40px;\n  color: #244070;\n  font-weight: bold;\n  margin: 0;\n  letter-spacing: 1px;\n}\n.drug-section {\n  margin: 0 auto 36px auto;\n  max-width: 820px;\n  font-size: 20px;\n  color: #243243;\n  background: #fffffff6;\n  border-radius: 18px;\n  box-shadow: 0px 4px 16px rgba(66,89,160,0.07);\n  overflow: hidden;\n  border: 1px solid #e4ecf3;\n}\n.section-bg {\n  background: linear-gradient(90deg,#e6f9f2 10%,#f5fafc 95%);\n  padding: 14px 24px;\n  border-bottom: 1px solid #ecf2f7;\n}\n.section-bg h2 {\n  margin: 0;\n  font-size: 26px;\n  color: #179382;\n  font-weight: bold;\n  display: flex;\n  align-items: center;\n  gap: 10px;\n}\n.drug-section ul {\n  padding: 18px 38px 14px 46px;\n  margin: 0;\n}\n.drug-section li {\n  padding-bottom: 10px;\n  line-height: 1.7;\n  font-size: 20px;\n}\n.drug-section strong {\n  color: #118881;\n  font-weight: 700;\n}\n.drug-section .emph {\n  background: #eaf0fa;\n  padding: 2px 10px;\n  border-radius: 8px;\n  font-size: 18px;\n  color: #295181;\n}\n.drug-section p {\n  font-size: 20px;\n  padding: 16px 42px;\n  margin: 0 0 4px 0;\n}\n.drug-ref {\n  background: #f4f9fd;\n  border-radius: 18px;\n  box-shadow: 0px 5px 12px rgba(53,89,147,0.06);\n  padding: 0px;\n}\n.ref-bg {\n  background: linear-gradient(84deg,#cde7ff 5%,#ebf7fc 80%);\n}\n.drug-ref ol {\n  margin: 0 32px 22px 38px;\n  padding-left: 12px;\n  font-size: 18px;\n}\n.drug-summary {\n  background: linear-gradient(91deg,#fcfefa 5%,#e6f6ee 95%);\n}\n\u003C/style>\n","\u003Cdiv id=\"material_title\" class=\"drug-title\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px ",567,"2025-09-10 16:48:21","纳武利尤单抗, 安全用药, 免疫治疗, 药物相互作用, 不良反应","本文全面解读纳武利尤单抗的用药指南，涵盖剂型、用法、药物相互作用及不良反应等关键信息，助患者安全有效用药。","2025-09-14 11:30:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]